Compare D Wave Quantum Inc (QBTS) vs TG Therapeutics Inc (TGTX) Price & Performance

D-Wave Quantum (QBTS) trades at $14.60, down 4.07% with a bearish technical signal despite unanimous analyst buy ratings and a $34.38 consensus target. The quantum computing company shows concerning fundamentals with a P/S ratio of 421.36 and negative profitability metrics, including a -2,001.59% net income margin. Recent quarterly earnings have been mixed, missing expectations in Q4 2025 and Q2 2026 while beating in Q1 2026.

While analyst optimism remains high with 100% buy ratings, significant financial risks persist including ongoing losses, negative cash flow projections for 2026, and multiple fraud investigations. The stock faces substantial execution risk in the competitive quantum computing space, though long-term potential exists if the company can achieve commercial scalability and positive cash flow generation.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.